成人急性淋巴细胞白血病外周血与骨髓可测量残留病的一致性
本研究采用二代测序(NGS)MRD平台,前瞻性观察接受细胞治疗(HCT和CAR-T)的成人ALL患者中外周血(PB)与骨髓(BM)MRD的相关性。69例患者共126对配对样本显示PB与BM MRD强相关(r=0.87;P<.001),PB检测灵敏度87%、特异性90%。HCT后复发患者100%在PB可检测到MRD(中位领先90天),CAR-T后复发患者85%在PB可检测到MRD(中位领先60天)。
要点
- 成人ALL细胞治疗后PB与BM的NGS-MRD强相关(r=0.87)
- PB检测MRD灵敏度87%、特异性90%,可作为BM的替代
- PB MRD可先于临床复发被检出,HCT后中位领先90天
核心结论
- 成人ALL接受细胞治疗时,PB与BM的NGS-MRD高度一致。
- PB MRD监测可作为频繁侵入性BM评估的合适替代。
研究设计与样本
- 前瞻性观察性研究,采用NGS-MRD平台。
- 纳入69例接受HCT或CAR-T的成人ALL患者,共126对PB/BM配对样本。
主要发现
- PB与BM MRD强相关(r=0.87;P<.001)。
- 以BM MRD为参照,PB检测MRD的灵敏度为87%、特异性为90%。
- HCT后复发患者中100%在PB可检出MRD,中位MRD阳性至临床复发时间90天。
- CAR-T后复发患者中85%在PB可检出MRD,中位MRD阳性至临床复发时间60天。
关键数值与推荐
- PB与BM MRD相关系数r=0.87(P<.001)。
- PB检测MRD灵敏度87%、特异性90%。
- HCT后复发者PB MRD检出率100%,中位领先90天。
- CAR-T后复发者PB MRD检出率85%,中位领先60天。
临床怎么用
- 在成人ALL细胞治疗后的MRD监测中,可考虑用PB NGS-MRD替代频繁BM穿刺。
- PB MRD阳性可预警复发,HCT后中位领先90天、CAR-T后中位领先60天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monitoring of measurable residual disease (MRD) is essential to the management of acute lymphoblastic leukemia (ALL) and is typically performed through repeated bone marrow (BM) assessments. Using a next-generation sequencing (NGS) MRD platform, we performed a prospective observational study evaluating the correlation between peripheral blood (PB) and BM MRD in adults with ALL receiving cellular therapies (hematopoietic cell transplantation [HCT] and chimeric antigen receptor T-cell [CAR-T] therapies). Among the study cohort (N = 69 patients; 126 paired PB/BM samples), we found strong correlation between PB and BM MRD (r = 0.87; P < .001), with a sensitivity and specificity of MRD detection in the PB of 87% and 90%, respectively, relative to MRD in the BM. MRD became detectable in the PB in 100% of patients who subsequently relapsed following HCT, with median time from MRD+ to clinical relapse of 90 days, and in 85% of patients who relapsed following CAR T, with median time from MRD+ to clinical relapse of 60 days. In adult patients with ALL undergoing cellular therapies, we demonstrate strong concordance between NGS-based MRD detected in the PB and BM. Monitoring of ALL MRD in the PB appears to be an adequate alternative to frequent invasive BM evaluations in this clinical setting.
引用
- Muffly L, Sundaram V, Chen C, et al. Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Adv. 2021. PMID: 34424318. doi:10.1182/bloodadvances.2021004234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。